Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]
, 2014 The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard +4 more
core +10 more sources
Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics [PDF]
, 2016 BACKGROUND: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with
A. Benfante +6 more
core +5 more sources
Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma. [PDF]
PLoS ONE, 2017 Interleukin-13 (IL-13) is associated with allergic airway inflammation and airway remodeling. Our group found a variant with a single nucleotide polymorphism in the IL13 gene at position +2044G>A (rs20541) that was expected to result in the non ...
Yutaka Nakamura +3 more
doaj +1 more source
Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]
, 2012 Peer reviewedPublisher ...
Walsh, Garry M.
core +2 more sources
Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]
, 2019 Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke +4 more
core +1 more source
Treatment of juvenile bullous pemphigoid with lebrikizumab. [PDF]
J Dtsch Dermatol GesWittenberg M +6 more
europepmc +3 more sources
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
American Journal of Clinical Dermatology, 2023 Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder characterized by chronic or relapsing eczematous lesions with intense pruritus and discomfort. Affected patients often experience significant impairment in their quality of life, and the treatment of moderate-to-severe AD forms remains challenging.
Diana Bernardo +2 more
openaire +2 more sources
Periostin as a biomarker of airway inflammation [PDF]
, 2016 No abstract ...
Johnstone, Steven, McSharry, Charles
core +1 more source
We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]
, 2018 Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4, +3 more
core +1 more source
Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]
, 2017 Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe +4 more
core +3 more sources